Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
75 76 Next >
News headline image
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies ↗
 
Via Benzinga
News headline image
US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs ↗
Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy. 
Via Benzinga
News headline image
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies ↗
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio. 
Via Benzinga
News headline image
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
From AstraZeneca
Via Business Wire
News headline image
Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
Health Care Company AstraZeneca Announces Acquisition of Icosavax ↗
 
Via Benzinga
News headline image
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am 
Via Benzinga
News headline image
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗
Friday, FDA approved AstraZeneca 
Via Benzinga
News headline image
These 3 Big Pharma Stocks Are Making Big Plays With AI ↗
Opportunity is in the air with AI, and these pharma giants are seizing the moment. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
From AstraZeneca
Via Business Wire
News headline image
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry ↗
Which weight-loss stocks are good buys today? 
Via The Motley Fool
News headline image
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside ↗
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
News headline image
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs ↗
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
News headline image
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the  
Via Benzinga
News headline image
Why Is Compugen (CGEN) Stock Up 189% Today? ↗
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences. 
Via InvestorPlace
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest? ↗
2024 is going to be a sizzler in the biopharma sector. 
Via The Motley Fool
News headline image
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
News headline image
Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock ↗
Tuesday brought favorable inflation data, and bullish investors are looking for stock winners. 
Via The Motley Fool
Topics Economy
News headline image
Why Is Icosavax (ICVX) Stock Up 46% Today? ↗
Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! 
Via InvestorPlace
News headline image
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M ↗
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash,... 
Via Benzinga
News headline image
Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why ↗
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation  
Via Benzinga
News headline image
AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease ↗
AstraZeneca Plc (NASDAQ: AZN)  
Via Benzinga
News headline image
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
From Alexion
Via Business Wire
News headline image
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024? ↗
It'll take a few years for its latest moves to pay off, assuming they do. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Now the Right Time to Buy AstraZeneca Stock? ↗
The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock. 
Via The Motley Fool
News headline image
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers ↗
The White House is endorsing a contentious power that permits the government to reclaim patents for specific  
Via Benzinga
Topics Intellectual Property
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.